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Impact of Parathyroidectomy on Renal Graft Function: A Single Center
Perspective
YH Chan, HW Chan, CY Cheung, KM Wong, A Liu, WL Chak, HS Wong,
KS Choi, KF Chau, CS Li
Renal Unit, Department of Medicine, Queen Elizabeth Hospital, Kowloon,
Hong Kong SAR, China.
Background and Methods: In this study, we retrospectively evaluated the
impact of parathyroidectomy (PTX) on renal graft function in stable renal
transplant recipients treated for persistent post-transplant hyperparathyroidism
in our center. All renal transplant recipients receiving PTX after renal transplant
from 1999 to 2005 were recruited. Serum creatinine (SCr) levels were measured
at pre-PTX, 1 month, 3 months and 6 months post-PTX. Changes in serum
[Ca] and [PO4], parathyroid hormone level (PTH), hemoglobin (Hb) and BP
control were also studied. Data were expressed in mean ( SD or median (IQR).
Results: Thirteen patients (M:F = 7:6) with a mean age of 44.0 ( 9.0 years
were recruited. PTX was performed at a median of 35.9 (68.6) months post-
transplant. Mean SCr before PTX was 142.5 ( 49.7 +mol/L. All patients received
calcium and vitamin D supplements post-PTX. Serum [Ca] and PTH levels
improved significantly after PTX (Table 1). Significant increases in patients’
SCr were observed at 1 month, 3 months and 6 months post-PTX (Table 2). No
significant changes in Hb (12.5 vs 12.3 g/dL, p = 0.36), mean arterial pressure
(91.1 vs 89.0 mmHg, p = 0.40) and number of anti-HT drugs used before and
after PTX were observed.
Table 1
Pre-PTX Post-PTX
Ca (mmol/L) 2.90 ( 0.12 2.49 ( 0.28*
PO4 (mmol/L) 0.96 ( 0.11 1.33 ( 0.17*
PTH (pmol/L) 33.5 ( 27.6 4.3 ( 7.2*
*p < 0.005.
Table 2
Pre-PTX 1 month 3 months 6 months
SCr (+mol/L) 142.5 ( 49.7 157.0 ( 40.9* 160.7 ( 44.8+ 161.1 ( 46.0+
% Change 113.3 ( 14.6* 115.2 ( 12.6+ 15.2 ( 9.4+
*p < 0.05; +p < 0.005.
Conclusion: PTX was effective in the management of post-transplant
hyperparathyroidism but was associated with deterioration in renal graft function
that persisted at 6 months post-PTX. The mechanism of the deterioration remains
to be elucidated.
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Background and Methods: Local data is lacking on the use of C4d in renal
graft biopsies. We report our experience on its application and attempt to find
out its prognostic significance. Renal graft biopsies performed between 1 April
2003 and 31 March 2005 were reviewed. Results: There were 42 biopsies, 25
(59.5%) from males. Mean age ( SD at biopsy was 44.85 ( 10.83. The primary
causes of renal failure included glomerulonephritis (26.2%), diabetes (16.7%),
hereditary (7.1%), unknown (40.5%), and others (9.5%). Duration of follow-
up was 11.4 ( 6.24 months. Histologic diagnoses included acute tubular necrosis
(ATN) (28.6%), acute cellular rejection (Banff 1997) (borderline, 9.5%; type I,
23.8%; type II, 2.4%), and others (35.7%). Sixteen of 42 (38.1%) were stained
C4d positive (10 focal, 6 diffuse). C4d positive and negative groups received
similar immunosuppression and demonstrated similar histologic findings, except
a higher prevalence of ATN (11/26 vs 2/16; p = 0.084) and arteriosclerosis
(6/26 vs 0/16; p = 0.067) in the latter group. C4d positive patients were more
likely to receive pulse steroid after renal biopsies (7/16 vs 3/26; p = 0.027) and
to have higher serum creatinine levels at 6 months (in +mol/L: 254.6 ( 129.7 vs
162.1 ( 63.9; p = 0.056). Nevertheless, graft survival (in months) did not differ
significantly [16.05 ( 1.73 vs 19.3 ( 1.74 (SE); p = 0.58]. Conclusion: Routine
C4d staining is needed as its status cannot be predicted by histologic findings.
Positive C4d staining is probably associated with poorer renal outcome.
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Background and Methods: To investigate the effects of cyclosporine (CsA)
and tacrolimus (TAC) on mycophenolic acid (MPA) pharmacokinetics, we
compared MPA profiles taken at 1 and 3 months post-transplant from renal
transplant patients receiving mycophenolate mofetil (MMF) (2 g/day) plus CsA
(n = 8) and MMF (1 g/day) plus TAC (n = 7). All patients received concomitant
prednisolone. Blood samples were taken at 0 (trough), 20, 40, 60, 75 and 90
minutes, and at 2, 4, 6, 8, 10 and 12 hours post-dose for each MPA profile.
Plasma MPA levels were determined by HPLC. Results: Mean MPA trough
levels were higher at both 1 and 3 months in the TAC group compared with the
CsA group (2.73 ( 1.20 vs 1.21 ( 0.42 +g/mL at 1 month, p < 0.005; 2.97 (
2.07 vs 1.24 ( 0.69 +g/mL at 3 months, p < 0.05). Mean MPA AUC0–12h in the
TAC and CsA groups were 40.5 ( 9.4 and 35.7 ( 5.0 +g*h/mL at 1 month
(p > 0.05), and 44.4 ( 17.2 and 43.2 ( 10.8 +g*h/mL at 3 months (p > 0.05),
respectively. A second peak was observed in MPA profiles in the TAC but not
the CsA group. When MPA levels were dose-normalized to 1 g MMF, mean
MPA trough, Cmax and AUC0–12h at 1 and 3 months were significantly higher in
the TAC group compared to the CsA group. Conclusion: These data suggest
that CsA affects MPA pharmacokinetics by interrupting the enterohepatic
recirculation of MPA. Using a 50% lower dose of MMF can achieve a similar
MPA exposure when used in combination with TAC compared to CsA. MMF
dose adjustment and drug monitoring may be necessary when CsA is switched
to TAC or vice versa.
